Document Detail


Is reporting of recurrence data important in pancreatic cancer?
MedLine Citation:
PMID:  14993026     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Therapeutic approaches to patients with pancreatic cancer have undergone a paradigm shift in recent years. However, little is known about the outcome of patients with recurrent pancreatic cancer who undergo treatment. The purpose of this study was to identify patients with recurrent pancreatic cancer and to determine whether treatment after recurrence had any effect on outcome. METHODS: A review of all patients undergoing surgical resection with curative intent revealed 70 patients with documented recurrence and complete medical records. Patients were grouped into three categories: group 1 included those who received treatment after recurrence (n = 45), group 2 included those who were not offered treatment (n = 9), and group 3 included those with poor performance status who received no treatment (n = 16). RESULTS: The median overall survival for the three groups was 26, 18, and 14.5 months for groups 1, 2, and 3, respectively (P <.00001). The median survival after recurrence was 10 months, 6 months, and 1 month, respectively, for the three groups (P <.0001). CONCLUSIONS: This is the first series we are aware of that compares the outcomes of patients who received treatment after recurrence of pancreatic cancer with the outcomes of those who received no treatment. In this series, it seems that patients who were well enough to tolerate additional therapy had a longer survival than those who received supportive care only. This may be important in the analysis of adjuvant therapy trials of pancreatic cancer with survival as an end point.
Authors:
Michael O Meyers; Ingrid M Meszoely; John P Hoffman; James C Watson; Eric Ross; Burton L Eisenberg
Related Documents :
23625306 - Percutaneous interspinous spacer versus open decompression: a 2-year follow-up of clini...
18556996 - Pancreatic resection with islet cell autotransplant for the treatment of severe chronic...
24787056 - Ocular surface changes in glaucomatous patients treated with and without preservatives ...
18374046 - Duodenum-preserving pancreatic head resection--a randomized controlled trial comparing ...
6837226 - Proximal gastric vagotomy. a prospective study of 829 patients with four-year follow-up.
6376076 - A new and effective technique of yag laser photocoagulation for severe upper gastrointe...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Annals of surgical oncology     Volume:  11     ISSN:  1068-9265     ISO Abbreviation:  Ann. Surg. Oncol.     Publication Date:  2004 Mar 
Date Detail:
Created Date:  2004-03-02     Completed Date:  2004-06-01     Revised Date:  2007-07-18    
Medline Journal Info:
Nlm Unique ID:  9420840     Medline TA:  Ann Surg Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  304-9     Citation Subset:  IM    
Affiliation:
Department of Surgery, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma / drug therapy,  pathology*,  surgery*
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Combined Modality Therapy
Data Collection
Databases, Factual
Female
Follow-Up Studies
Humans
Male
Middle Aged
Neoplasm Recurrence, Local / drug therapy,  pathology*,  surgery*
Pancreatic Neoplasms / drug therapy,  pathology*,  surgery*
Prognosis
Survival Analysis
Time Factors
Treatment Outcome

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Surgery for hepatocellular carcinoma: does it improve survival?
Next Document:  Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer.